Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Université de Montréal

$105,000.00

Phenomic approaches for the functional characterization of drug targets

FY 2016-17

Summary
Drug development is time-consuming and very expensive. One of the solutions to alleviate the problem is the repurposing of approved drugs for new disease indications. Successful examples of such drug repurposing, however, often emerge from coincidental discoveries and there is room for improvement. In this project, we propose to use a novel approach that uses large genetic datasets for the repurposing of drugs. More specifically, we will do this by studying the genes that encode the proteins that are targeted by cardiovascular drugs. Recent studies have shown that individuals with mutations in drug targets can have clinical manifestations that mimic the action of the medication. For example, statins are one of the most prescribed drug classes in Canada for the reduction of cholesterol. Individuals with mutations in the gene encoding the drug target of statins were shown to have lower blood cholesterol levels and lower coronary artery diseases, similar to statin users. Following on this concept, in our study we propose to search for clinical presentations in individuals that have mutations in drug targets of cardiovascular drugs. We will use data from 150,000 individuals to the UK Biobank and over 10,600 participants to the Montreal Heart Institute Biobank, which are observational cohorts that include detailed medical information along with large genomic datasets. We will also develop the informatics tools necessary for such studies and we will make them available to the research community. Replication and validation of our findings will be possible by using data from over 27,000 participants to clinical drug trials that include patients using the tested cardiovascular drugs. This approach leverages a large collection of clinical and genomic datasets to discover new clinical uses for existing cardiovascular drugs.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365439
Name
Legault Marc-Andre
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Phenomic approaches for the functional characterization of drug targets
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Drug Repurposing; Drug Target; Genomics; Phewas
Abstract
Drug development is time-consuming and very expensive. One of the solutions to alleviate the problem is the repurposing of approved drugs for new disease indications. Successful examples of such drug repurposing, however, often emerge from coincidental discoveries and there is room for improvement. In this project, we propose to use a novel approach that uses large genetic datasets for the repurposing of drugs. More specifically, we will do this by studying the genes that encode the proteins that are targeted by cardiovascular drugs. Recent studies have shown that individuals with mutations in drug targets can have clinical manifestations that mimic the action of the medication. For example, statins are one of the most prescribed drug classes in Canada for the reduction of cholesterol. Individuals with mutations in the gene encoding the drug target of statins were shown to have lower blood cholesterol levels and lower coronary artery diseases, similar to statin users. Following on this concept, in our study we propose to search for clinical presentations in individuals that have mutations in drug targets of cardiovascular drugs. We will use data from 150,000 individuals to the UK Biobank and over 10,600 participants to the Montreal Heart Institute Biobank, which are observational cohorts that include detailed medical information along with large genomic datasets. We will also develop the informatics tools necessary for such studies and we will make them available to the research community. Replication and validation of our findings will be possible by using data from over 27,000 participants to clinical drug trials that include patients using the tested cardiovascular drugs. This approach leverages a large collection of clinical and genomic datasets to discover new clinical uses for existing cardiovascular drugs.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Legault, Marc-Andre
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Université de Montréal - $105,000 Grant (2016-17) | Canada Spends